#UKIM Podcast – UK Property Shares, #AVCT Avacta, and #ECR ECR Minerals with Alan Green

The UK Investor Magazine was thrilled to welcome Alan Green back to the Podcast to discuss a selection of UK shares and the macroeconomic backdrop. Register for Investment Trust Conference here. We discuss: Barratt Developments (LON:BDEV) Avacta (LON:AVCT) ECR Minerals (LON:ECR) UK CPI inflation surprisingly fell to 6.7% in the year to August from 6.8% […]

#POLB Poolbeg Pharma PLC – Annual Report & AGM Notice

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting (“AGM”) 2022 have been posted to shareholders.   The 2022 […]

#ORPH Open Orphan – PLC Notice of results

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2022 on 8 September 2022.    Investor presentation   Yamin ‘Mo’ Khan, Chief […]

#ORPH Open Orphan – Launch of STRiVE project

Respiratory viral strains suitable for challenge agents being collected from consenting volunteers   Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has recently launched the STRiVE […]

#POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution

31 January, 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirms that it has signed the licence to AnaBio Technologies’ (‘AnaBio’) microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform. This follows the binding term sheet announced on […]

#POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick

17 January, 2022- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, […]

#POLB Poolbeg Pharma – Poolbeg to develop oral vaccine delivery platform

16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full licence and collaboration agreement to follow. The partnership allows Poolbeg exclusive access to AnaBio’s microencapsulation and nanoencapsulation […]

#ORPH Open Orphan Plc – Positive results from Flu Human Challenge Study

Open Orphan plc (AIM: ORPH) a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, notes the announcement released from SAB Biotherapeutics (NASDAQ: SABS) (“SAB”), reporting positive results from a human challenge study testing SAB-176, its investigational therapeutic for the treatment of seasonal influenza. hVIVO, a subsidiary […]